Logo

Skyhawk Therapeutics Expands its Agreement with Merck to Develop Novel Small Molecules Modulating RNA Splicing

Share this

Skyhawk Therapeutics Expands its Agreement with Merck to Develop Novel Small Molecules Modulating RNA Splicing

Shots:

  • Skyhawk will deploy its SkySTARTM platform to develop drug candidates targeting autoimmune and metabolic diseases and will receive an up front $600M/target while Merck get an option to exclusively license WW IP rights to candidates- discovered and developed under the agreement
  • If Merck exercises its option- Skyhawk will receive an option fees- milestones and royalties on sales of approved products resulting from the collaboration while Merck will be responsible for development & commercialization. The collaboration now covers neurodegeneration- oncology- autoimmunity- and metabolic diseases
  • The expanded collaboration in autoimmune and metabolic diseases reflects SkySTARTM platform's ability to advance small molecules- addressing the unmet medical needs of patients

Click here ­to­ read full press release/ article 

Ref: PRNewswire | Image: Merck 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions